M.D. Anderson Cancer Center
To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.
PRIMARY OBJECTIVE • To compare time to next treatment (TTNT), defined as the time from randomization to initiation of new lymphoma directed systemic therapy, between participants with previously untreated, low tumor burden follicular lymphoma treated with epcoritamab versus watchful waiting.
ELIGIBILITY CRITERIA * Histologically diagnosed follicular lymphoma grade 1-3a * Within 6 months from the diagnosis of follicular lymphoma * Have no prior systemic treatment for lymphoma * Stage II (non-contiguous), III or IV disease * Age ≥18 years * Performance status ≤2 on the ECOG scale * Low-tumor burden disease based on GELF criteria26 \> No nodal or extranodal (except spleen) mass \> 7 cm in its greater diameter * No 3 nodal or extranodal sites ≥ 3 cm in diameter * No presence of at least one B symptom ▪ B symptoms: Fever (\>38 ℃), night sweats, weight loss \> 10% in the past 6…
Given by Injection
Participant will be closely monitored until the disease gets worse and requires treatment, as determined by your treating doctor or at your request.
Arctuva estimate
Verify or correct the compensation shown for this listing.